Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0140-6736(89)90582-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Antimalarial drug toxicity: a review.
Drug Saf
May 2004
WHO/Tropical Disease Research, Geneva, Switzerland.
Malaria, caused mostly by Plasmodium falciparum and P. vivax, remains one of the most important infectious diseases in the world. Antimalarial drug toxicity is one side of the risk-benefit equation and is viewed differently depending upon whether the clinical indication for drug administration is malaria treatment or prophylaxis.
View Article and Find Full Text PDFAn integrated assessment of the clinical safety of artemether-lumefantrine: a new oral fixed-dose combination antimalarial drug.
Trans R Soc Trop Med Hyg
February 2001
Novartis Pharma AG, Basle, Switzerland.
Artemether-lumefantrine (A-L), a new fixed-dose oral antimalarial drug, combines the fast onset of action of artemether (an artemisinin derivative) in terms of parasite clearance with the high cure rate of lumefantrine in the treatment of acute uncomplicated Plasmodium falciparum malaria. The extensive clinical trial database of A-L has allowed a comprehensive evaluation of its tolerability and safety in a total of 1869 patients (including 243 children aged 5-12 years and 368 children aged < 5 years). The most commonly reported and possibly related adverse effects following A-L therapy involved the gastro-intestinal (abdominal pain, anorexia, nausea, vomiting, diarrhoea) and central nervous (headache, dizziness) systems.
View Article and Find Full Text PDFComparative efficacy of chloroquine plus chlorpheniramine and halofantrine in acute uncomplicated falciparum malaria in Nigerian children.
Trans R Soc Trop Med Hyg
December 1998
Department of Pharmacology and Therapeutics, University of Ibadan, Nigeria.
In the face of growing chloroquine resistance of Plasmodium falciparum, efforts to prolong the clinical usefulness of the drug have partly concentrated on its combination with potential resistance-reversing compounds. However, clinical studies on such combinations have been limited. We have compared the efficacy of halofantrine, an arylaminoalcohol effective in chloroquine resistant malaria, and a combination of chloroquine plus chlorpheniramine, a histamine H1 receptor antagonist which reverses chloroquine resistance of P.
View Article and Find Full Text PDFClinical pharmacokinetics of halofantrine.
Clin Pharmacokinet
August 1994
Department of Clinical Tropical Medicine and Hospital for Tropical Diseases, Bangkok, Thailand.
Halofantrine is a phenanthrenemethanol antimalarial that is effective against asexual forms of multidrug-resistant Plasmodium falciparum malaria. It has no action on gametocytes or hypnozoites in the liver. The drug is administered as a racemic mixture but the (+)- and (-)-enantiomers show no difference in activity in vitro.
View Article and Find Full Text PDFEfficacy of micronized halofantrine in semi-immune patients with acute uncomplicated falciparum malaria in Cameroon.
Antimicrob Agents Chemother
September 1993
Laboratoire de Parasitologie, Centre National de Référence de la Chimiosensibilité du Paludisme, Hôpital Bichat-Claude Bernard, Paris, France.
Fifty subjects with acute uncomplicated falciparum malaria were treated orally with a new micronized formulation of halofantrine. The dose given corresponded to one-half the normal dose for the standard formulation. Parasitemia cleared in all subjects within 78 h.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!